Cantor Fitzgerald Issues Negative Outlook for NBIX Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Equities research analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Neurocrine Biosciences in a research note issued on Friday, April 25th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings per share of $4.20 for the year, down from their prior forecast of $4.21. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%.

Several other equities research analysts have also recently issued reports on the stock. Needham & Company LLC upgraded shares of Neurocrine Biosciences from a "hold" rating to a "buy" rating and set a $138.00 price objective for the company in a research report on Tuesday, April 15th. Bank of America dropped their price objective on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating for the company in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft started coverage on shares of Neurocrine Biosciences in a research note on Tuesday, February 11th. They set a "hold" rating and a $138.00 target price for the company. Royal Bank of Canada upgraded Neurocrine Biosciences from a "sector perform" rating to an "outperform" rating and cut their target price for the stock from $138.00 to $137.00 in a research report on Monday, April 14th. Finally, Canaccord Genuity Group lowered their target price on Neurocrine Biosciences from $163.00 to $158.00 and set a "buy" rating on the stock in a research note on Monday. Three investment analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences presently has an average rating of "Moderate Buy" and an average price target of $160.90.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock traded up $0.78 during trading on Monday, reaching $107.24. 914,081 shares of the company were exchanged, compared to its average volume of 1,069,070. Neurocrine Biosciences has a 52-week low of $84.23 and a 52-week high of $157.98. The company has a market capitalization of $10.61 billion, a P/E ratio of 32.60, a PEG ratio of 0.77 and a beta of 0.33. The stock's 50 day simple moving average is $107.00 and its two-hundred day simple moving average is $122.16.

Institutional Trading of Neurocrine Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of NBIX. Caprock Group LLC acquired a new position in Neurocrine Biosciences in the fourth quarter worth approximately $236,000. Charles Schwab Investment Management Inc. increased its position in shares of Neurocrine Biosciences by 2.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 762,557 shares of the company's stock valued at $104,089,000 after purchasing an additional 15,266 shares during the period. Tri Ri Asset Management Corp bought a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at approximately $3,236,000. Oakworth Capital Inc. acquired a new stake in shares of Neurocrine Biosciences during the 4th quarter worth about $379,000. Finally, Avantax Advisory Services Inc. raised its stake in shares of Neurocrine Biosciences by 11.4% in the fourth quarter. Avantax Advisory Services Inc. now owns 2,895 shares of the company's stock valued at $395,000 after acquiring an additional 297 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company's stock.

Insiders Place Their Bets

In other news, CEO Kyle Gano sold 1,541 shares of the firm's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.87, for a total transaction of $235,572.67. Following the completion of the transaction, the chief executive officer now owns 136,778 shares in the company, valued at approximately $20,909,252.86. This trade represents a 1.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Julie Cooke sold 1,740 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $152.89, for a total value of $266,028.60. Following the sale, the insider now owns 18,202 shares of the company's stock, valued at $2,782,903.78. This trade represents a 8.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,801 shares of company stock valued at $2,834,677 over the last three months. Company insiders own 4.30% of the company's stock.

Neurocrine Biosciences announced that its Board of Directors has approved a share repurchase program on Friday, February 21st that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 4.2% of its shares through open market purchases. Shares buyback programs are often an indication that the company's leadership believes its shares are undervalued.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.